摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

dl-epinephrine-3-O-sulfate | 112346-91-5

中文名称
——
中文别名
——
英文名称
dl-epinephrine-3-O-sulfate
英文别名
hydron;[2-hydroxy-5-[1-hydroxy-2-(methylamino)ethyl]phenyl] sulfate
dl-epinephrine-3-O-sulfate化学式
CAS
112346-91-5
化学式
C9H13NO6S
mdl
——
分子量
263.271
InChiKey
UVOUYHHCKBJLOS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.545±0.06 g/cm3(Predicted)
  • 溶解度:
    DMSO(少许)、水(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    -4.2
  • 重原子数:
    17
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    125
  • 氢给体数:
    4
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    肾上腺酮氯磺酸 、 sodium tetrahydroborate 作用下, 以 甲醇异丙醇 为溶剂, 反应 8.0h, 生成 dl-epinephrine-3-O-sulfate
    参考文献:
    名称:
    Improved synthesis of sulfoconjugate isomers of norepinephrine and epinephrine,and separation of all sulfoconjugates of catecholamines by thin-layer and high-performance liquid chromatography.
    摘要:
    通过还原去甲肾上腺素酮和肾上腺素酮的相应硫酸盐,开发了合成去甲肾上腺素和肾上腺素的 3-O- 和 4-O- 磺化共轭物的方法。通过薄层色谱法和高效液相色谱法同时分离了儿茶酚胺的六种硫代轭化合物。
    DOI:
    10.1248/cpb.29.2086
点击查看最新优质反应信息

文献信息

  • Novel trifluoromethylepinephrine compounds and methods of making and using thereof
    申请人:——
    公开号:US20040015015A1
    公开(公告)日:2004-01-22
    Disclosed herein are trifluoromethylepinephrine compounds having the following structural formula (I) 1 wherein R 1 -R 5 are each independently selected from the group consisting of H, alkyl, alkoxyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, acyl, thioacyl, sulfonyl mercapto, alkylthio, carboxy, amino, alkylamino dialkylamino, carbamoyl, arylthio, and heteroarylthio; wherein X, Y, and Z are each independently selected from the group consisting of H or trifluoromethyl with the proviso that at least one of which is trifluoromethyl. Also disclosed are pharmaceutical compositions comprising the trifluoromethylepinephrine compounds and methods of making and using thereof. Novel trifluoroepinephrine intermediates are also disclosed.
    本文披露了具有以下结构式(I)的三甲基肾上腺素化合物 其中R1-R5分别独立地选自H、烷基、烷氧基、芳基、杂芳基、环烷基、杂环烷基、酰基、酰基巯基、烷基、羧基、基、烷基基二烷基基、基甲酰基、芳基基和杂芳基基的群组;其中X、Y和Z分别独立地选自H或三甲基,但至少其中之一是三甲基。还披露了包含三甲基肾上腺素化合物的药物组合物以及制备和使用方法。还披露了新颖的三肾上腺素中间体。
  • Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
    申请人:Vyteris, Inc.
    公开号:EP1586347A1
    公开(公告)日:2005-10-19
    Highly shelf-stable electrically assisted transdermal drug delivery systems for deliverir g epinephrine, typically with an anesthetic such as lidocaine, are provided along with methods for making the highly shelf-stable epinephrine-containing transdermal deliver device. Highly shelf-stable packaged electrode assemblies for transdermal delivery of epinephrine also are provided.
    提供了用于输送肾上腺素(通常与利多卡因麻醉剂一起)的高货架稳定性电辅助透皮给药系统,以及制造高货架稳定性含肾上腺素透皮给药装置的方法。还提供了用于透皮给药肾上腺素的高货架稳定性包装电极组件。
  • More potent and less toxic formulations of epinephrine and methods of medical use
    申请人:Taneja Jugal K.
    公开号:US10004700B1
    公开(公告)日:2018-06-26
    The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine, including autoinjection for treating anaphylaxis.
    本发明提供了比现有肾上腺素药物制剂药效更强、毒性更低的左旋肾上腺素(l-epinephrine)药物制剂,以及生产和使用这些 l-epinephrine药物制剂的方法,包括用于治疗过敏性休克的自动注射。
  • Epinephrine formulations
    申请人:PAR PHARMACEUTICAL, INC.
    公开号:US10130592B2
    公开(公告)日:2018-11-20
    Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.
    包含肾上腺素的药物组合物、给药方法和制造方法。组合物可包含活性剂、pH 值升高剂、抗氧化剂、过渡属络合剂、pH 值降低剂、补液调节剂中的至少一种,也可选择包含防腐剂和溶剂。
  • High-pH solid-state epinephrine formulation
    申请人:HARC Therapeutics AG
    公开号:US10478406B2
    公开(公告)日:2019-11-19
    Epinephrine formulated in aqueous solvent at a basic pH of about 8.5 remains in solid state. My data show that epinephrine formulated at a pH of about 8.5 is surprisingly resistant to oxidation. I here teach how to formulate solid-state epinephrine in basic solution, and how to use solid-state epinephrine to make pharmaceutical dosage forms.
    在碱性 pH 值约为 8.5 的溶剂中配制的肾上腺素保持固态。我的数据显示,在 pH 值约为 8.5 的条件下配制的肾上腺素具有惊人的抗氧化性。我在此教授如何在碱性溶液中配制固态肾上腺素,以及如何使用固态肾上腺素制作药物剂型。
查看更多